164 related articles for article (PubMed ID: 7508788)
1. Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.
Soloway MS; Hachiya T; Ruiz HE; Gomez CC; Civantos F
World J Urol; 1993; 11(4):221-6. PubMed ID: 7508788
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
[TBL] [Abstract][Full Text] [Related]
3. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
Abbas F; Kaplan M; Soloway MS
Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
[TBL] [Abstract][Full Text] [Related]
4. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
[TBL] [Abstract][Full Text] [Related]
6. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
7. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].
Miyamae K; Kitani K; Miyamoto K; Hamada S; Kawano T; Maehara A; Otsuka Y; Otsuka T; Hamada Y
Nihon Hinyokika Gakkai Zasshi; 2009 Jul; 100(5):570-5. PubMed ID: 19663244
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Eur Urol; 1993; 24(4):450-5. PubMed ID: 7507045
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant hormonal deprivation before radical prostatectomy.
Sassine AM; Schulman CC
Eur Urol; 1993; 24 Suppl 2():46-50. PubMed ID: 7505231
[TBL] [Abstract][Full Text] [Related]
11. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
Oesterling JE; Andrews PE; Suman VJ; Zincke H; Myers RP
J Urol; 1993 Apr; 149(4):779-82. PubMed ID: 7681117
[TBL] [Abstract][Full Text] [Related]
12. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
14. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
[TBL] [Abstract][Full Text] [Related]
15. Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
Voges GE; Mottrie AM; Fichtner J; Mappes C; Störkel S; Stöckle M; Hohenfellner R
Eur Urol; 1995; 28(3):209-14. PubMed ID: 8536774
[TBL] [Abstract][Full Text] [Related]
16. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
Ornstein DK; Smith DS; Andriole GL
Urology; 1998 Dec; 52(6):1094-7. PubMed ID: 9836561
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.
Freeman JA; Lieskovsky G; Grossfeld G; Esrig D; Stein JP; Cook DW; Petrovich Z; Chen SC; Groshen S; Skinner DG
Urology; 1994 Nov; 44(5):719-25. PubMed ID: 7526528
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
